Earnings Outlook For Canadian Natural Res

Canadian Natural Res (NYSE:CNQ) is set to give its latest quarterly earnings report on Thursday, 2023-05-04. Here’s what…

Canadian Natural Res (NYSE:CNQ) is set to give its latest quarterly earnings report on Thursday, 2023-05-04. Here’s what investors need to know before the announcement.

Analysts estimate that Canadian Natural Res will report an earnings per share (EPS) of $1.23.

Canadian Natural Res bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.19, which was followed by a 2.34% increase in the share price the next day.

Here’s a look at Canadian Natural Res’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 1.65 2.10 2.31 1.89
EPS Actual 1.46 2.37 2.55 2.26
Price Change % 2.34% 2.0% 2.26% -0.2%

eps graph

Stock Performance

Shares of Canadian Natural Res were trading at $57.25 as of May 02. Over the last 52-week period, shares are down 10.74%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

To track all earnings releases for Canadian Natural Res visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF